FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
RegulatoryapprovedKeytrudaKeytruda QlexTrodelvyPositive
AI Analysis
Summary
The FDA approved Keytruda and Keytruda Qlex, each combined with Trodelvy, for first-line treatment of PD-L1+ advanced triple-negative breast cancer. This approval represents a significant expansion of pembrolizumab's use in TNBC and validates the combination approach with Trodelvy.
Outcome Details
FDA approved Keytruda and Keytruda Qlex, each with Trodelvy for first-line treatment of PD-L1+ (CPS ≥10) advanced triple-negative breast cancer
Importance:9/10
Sentiment:
0.90
FDA approvaloncologybreast cancerimmunotherapycombination therapy
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 25, 2026 2:07 AM